INSIDER · CIK 1810417
Sullivan Christopher Ryan
Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX)
↗6 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$1.8MSold on the market
1Companies
Sep 18, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 202616:10 | Sep 16, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $16.33 | −12,394 | 39,900 | -24% | −$202K | ||
| Sep 18, 202616:10 | Sep 16, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $9.88 | +12,394 | 52,294 | +31% | $122K | ||
| Sep 11, 202616:10 | Sep 10, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $17.62 | −10,185 | 39,900 | -20% | −$179K | ||
| Sep 11, 202616:10 | Sep 10, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $8.04 | +10,185 | 50,085 | +26% | $82K | ||
| Aug 19, 202616:10 | Aug 18, 2026from Aug 17, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $19.94 | −72,725 | 39,900 | -65% | −$1.5M | ||
| Aug 19, 202616:10 | Aug 18, 2026from Aug 17, 2026 | AVTXAvalo Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $9.88 | +71,852 | 70,931 | — | $710K |